Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;70(9):389-400.
doi: 10.1055/a-1217-2397. Epub 2020 Aug 3.

Coronavirus Disease-2019 (COVID-19): An Updated Review

Affiliations

Coronavirus Disease-2019 (COVID-19): An Updated Review

Mithun Rudrapal et al. Drug Res (Stuttg). 2020 Sep.

Abstract

The current outbreak of novel Coronavirus Disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major pandemic situation and a catastrophe for humans. COVID-19 is a severe infectious disease particularly of the respiratory system characterized by fatal complications such as severe acute respiratory distress syndrome (SARS), pneumonia, cardiac arrhythmia, kidney failure/ multiple organ failure and even death. Since its discovery, the SARS-CoV-2 has spread across 213 countries or territories, causing more than 8.5 million people with a rising death toll over 5.5 million people (as of June 2020, WHO). In fact, the current looming crisis of COVID-19 has become an increasingly serious concern to public health. It has affected lives of millions of people with severe impact on health systems and economies globally. Since there are no specific drugs and/or vaccines available so far, combating COVID-19 remains to be a major challenging task. Therefore, development of potential and effective treatment regimens (prophylactic/therapeutic) is urgently required which could resolve the issue. In this review, we summarize the current knowledge about the coronavirus, disease epidemiology, clinical manifestations and risk factors, replication of the virus, pathophysiology and host immune responses of SARS-CoV-2 infection. The therapeutic interventions and prophylactic measures along with precautionary measures are the frontline approaches that could be undertaken in order to control and prevent the spread of the deadly and highly contagious COVID-19 are also detailed herein.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Replication cycle of SARS-CoV-2 Step-1: Binding and entry of viral particle via membrane fusion or endocytosis on interaction of S1 protein with ACE2 receptor; Step-2: Release of nCoV genome and translation of viral glycoprotein, which occurs at host ribosome; Step3: Formation of replication-transcription complex (RCT) (RNA genome,-sense) with the enzyme replicase; Step 4: Formation of genomic and subgenomic RNA (sgRNA,+sense), and sgRNA transcription for N, S1, M and E proteins.; Step 5: Replication of genomic RNA (sRNA,+sense); Step 6: Translation of viral structural proteins (S, M, E protein on endoplasmic reticulum (ER) membrane); Step 7: S, E, M proteins combine with nucleocapsid (N in cytoplasm), and CoV genome at ER-golgi intermediate compartment; Step 8: CoV inside golgi vesicle, assembly of mature virion and release by exocytosis.
Fig. 2
Fig. 2
Pathophysiology of SARS-CoV-2 infection.
Fig. 3
Fig. 3
Immune responses of SARS-COV-2 induced respiratory infection.
Fig. 4
Fig. 4
Phases of SARS-COV-2 infection.
Fig. 5
Fig. 5
Cytokine storm induced by SARS-COV-2 infection and associated inflammatory reactions and multiorgan failure Abbreviations: CVS - Cardiovascular system, GIT - Gastrointestinal tract, SARS – Severe acute respiratory syndrome

References

    1. Coronavirus disease (COVID-19 Pandemic). Available from URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019; (accessed on 17/06/2020)
    1. COVID-19: Prevention & Investigational Treatments. Available from URL: https://www.drugs.com/condition/covid-19.html; (accessed on 19/06/2020)
    1. Berlin D A, Gulick R M, Martinez F J. Severe Covid-19. N Engl J Med. 2020:1–10. - PubMed
    1. Yi Y, Lagniton PN P, Ye S et al.COVID-19: What has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16:1753–1766. - PMC - PubMed
    1. Wang L, Wang Y, Ye D et al.Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105948. - DOI - PMC - PubMed

MeSH terms